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Abstract
Platinum-based chemotherapeutics exert their therapeutic efficacy via the formation of DNA 
adducts which interfere with DNA replication, transcription and cell division and ultimately 
induce cell death. Repair and tolerance of these Pt-DNA lesions by nucleotide excision repair 
(NER) and homologous recombination (HR) can substantially reduce the effectiveness of therapy. 
Inhibition of these repair pathways, therefore, holds the potential to sensitize cancer cells to Pt 
treatment and increase clinical efficacy. Replication Protein A (RPA) plays essential roles in both 
NER and HR, along with its role in DNA replication and DNA damage checkpoint activation. 
Each of these functions is, in part, mediated by RPA binding to single-stranded DNA (ssDNA). 
Here we report the synthesis and characterization of novel derivatives of RPA small molecule 
inhibitors and their activity in models of epithelial ovarian cancer (EOC) and non-small cell lung 
cancer (NSCLC). We have synthesized analogs of our previously reported RPA inhibitor 
TDRL-505 and determined the structure activity relationships. These data led us to the 
identification of TDRL-551, which exhibited a greater than 2-fold increase in in vitro activity. 
TDRL-551 showed synergy with Pt in tissue culture models of EOC and in vivo efficacy, as a 
single agent and in combination with platinum, in a NSCLC xenograft model. These data 
demonstrate the utility of RPA inhibition in EOC and NSCLC and the potential in developing 
novel anticancer therapeutics that target RPA-DNA interactions.
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1. Introduction
Platinum (Pt)-based combination chemotherapy has been the front-line treatment for a 
variety of malignancies including testicular, lung, and ovarian cancer [1]. However, 
resistance to Pt-based regimens remains a major limitation in the successful treatment for 
many of these cancers including epithelial ovarian cancer (EOC) and non-small cell lung 
cancer (NSCLC) [2;3]. More than 80% of EOC patients relapse with Pt-resistant disease, 
where second line therapies are largely ineffective. Thus, ovarian cancer has been clinically 
designated as the most deadly gynecological cancer owing to extremely poor prognosis and 
overall low survival rates [4]. The clinical efficacy of cisplatin is a function of its ability to 
cross-link DNA thereby blocking DNA replication, transcription and cell division. 
Ultimately Pt- treatment induces apoptosis [5;6], however, the balance between DNA 
damage and DNA repair dictates the extent of tumor death. While Pt-resistance is 
multifactorial, increased DNA repair is a major contributor [7]. Hence, exploiting DNA 
repair as a target to sensitize cells to Pt-based chemotherapy holds immense potential for 
increasing the survival rates in cancer therapy.
Repair and tolerance of cisplatin-DNA adducts occur primarily via nucleotide excision 
repair (NER) and homologous recombination (HR) [4;8;9]. Approximately 95% of Pt-DNA 
lesions formed by cisplatin are intrastrand crosslinks with the remaining ~5% being 
interstrand crosslinks and a small number of mono-lesions [10]. There is evidence for and 
against each lesion type being the cytotoxic lesion caused by cisplatin. Interstrand lesions 
are less abundant and repaired more efficiently than intrastrand lesions [11;12], and involve 
the HR pathway in conjunction with the FANC protein complex (a group of proteins 
associated with Fanconi anemia)[13]. Interstand adducts are more cytotoxic with estimates 
to as few as 20 interstrand crosslinks causing cell death if left unrepaired [14]. While more 
abundant and repaired slower [15;16], intrastrand lesions are better tolerated via HR and 
bypass polymerases [17]. Repair of intrastrand crosslinks occurs via the NER pathway [4] 
Therefore, while the exact lesion responsible for clinical efficacy remains to be determined, 
what is clear is that both NER and HR have differential and contributory roles in the cellular 
sensitivity to cisplatin.
Replication protein A (RPA) is the major human ssDNA binding protein and is required for 
both NER and HR [18]. The RPA heterotrimer consists of 70 kDa, 32 kDa and 14 kDa 
subunits with the 70-kDa subunit containing the two major high affinity DNA binding 
domains (DBD) DBD A and B, as well as DBD C and F. DBD D and E are in the 32-kDa 
and 14-kDa subunit, respectively. Binding to short stretches of ssDNA (~ 8–10 nucleotides) 
is primarily mediated by DBD A and B, while intermediate length ssDNA (~ 12–23 
nucleotides) also involves DBD C. Longer length ssDNA (~ 28–30 nucleotides) engages 
DBD D in addition to DBDs A, B and C [19–21]. RPA plays essential and non-redundant 
roles in both NER and HR, apart from its role in replication and DNA damage checkpoint 
activation [18]. Each of these roles requires binding of RPA to ssDNA, making RPA-DNA 
interaction a promising target for anti-cancer therapeutic activity in combination with 
cisplatin.
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Structural analysis of RPA reveals unique protein-DNA interactions that would facilitate the 
design of potent and selective small molecule inhibitors (SMIs) [22]. It has been also shown 
that genetic mutants of RPA display defects in DNA repair without impacting DNA 
replication and vice versa [18;23;24]. This separation of function can be exploited by using 
chemical probes that exclusively interfere with the DNA repair pathway and that, in 
conjunction with DNA-damaging agents, would offer a new possibility for cancer treatment. 
Our group has previously reported both reversible and irreversible chemical inhibitors of 
RPA [25–28]. The reversible inhibitor TDRL-505 exhibits synergistic effects with DNA 
damaging agents in a lung cancer cell model. This small molecule hinders the binding of 
DBD A and B of RPA to ssDNA, which according to in silico docking analysis occurs as a 
consequence of its interaction with DBD B and the DBD A-B interdomain [27]. In the 
present study we screened a series of analogs TDRL-505 in vitro and evaluated their activity 
in an EOC cell culture model. Structure activity relationship (SAR) data led us to an 
enhanced lead compound, TDRL-551. Herein we report the in vitro, cellular and in vivo 
activity of the RPA inhibitor TDRL-551 in models of lung and ovarian cancer.
2. Materials and Methods
2.1 Protein Purification
Full length, heterotrimeric human RPA (fl-RPA) was expressed in E. coli and purified by a 
three column procedure as previously described [29]. The DBD-A/B construct was 
expressed as a SUMO-His6-RPA181–432 fusion protein. E. coli BL21 (DE3) cells in log 
growth were induced for 3 hours with 0.5mM IPTG at 37°C. The cells were lysed in buffer 
containing 50mM Tris pH 7.5, 300 mM NaCl, 10% sucrose, 10mM imidazole, 25 μg/ml 
lysozyme, 1 μg/ml leupeptin, 1 μg/ml pepstatin and 0.5 mM PMSF. The lysate was loaded 
onto a Ni-NTA column washed and then incubated overnight with wash buffer containing 3 
μg/ml ULP1 protease to cleave the SUMO tag. The cleaved His6-RPA181–432 was eluted 
from the Ni-NTA column with elution buffer containing 350mM imidazole. The His6-RPA 
was then further purified on a size exclusion column (SEC) to remove the cleaved SUMO 
tag fragment. The SEC pool was then concentrated and stored at -80°C.
2.2 Electrophoretic Mobility Shift Assays (EMSA)
EMSA reactions (20 μL) were performed with 50 nM fl-RPA and 2.5 nM 5’[32P]-labeled 
34-base DNA in buffer containing 20mM HEPES (pH 7.0), 1mM DTT, 0.001% NP-40, 100 
mM NaCl, 5 mM MgCl2 and 50 μg/ml bovine serum albumin (BSA). Chemical compounds, 
either purchased from ChemDiv or synthesized in our laboratory, were suspended in DMSO 
and titrated as detailed in each figure. The DMSO concentration in the reaction mixture was 
kept constant at or below5%. RPA was incubated with inhibitor or DMSO control in 
reaction buffer for 30 minutes before the addition of DNA. Reactions were incubated for 5 
minutes at room temperature and products separated via 6% native polyacrylamide gel 
electrophoresis. The bound and unbound fractions were then quantified by phosphor-imager 
analysis using ImageQuant software (Molecular Dynamics, CA) and IC50 values calculated 
by non-linear regression using SigmPlot (Sysat). For EMSA reactions with RPA DBD-A/B, 
150 nM DBD-A/B was used and electrophoresis was performed at 4° C. All other conditions 
were identical to those described for the full length RPA.
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2.3 Chemical Synthesis
2.3.1 General—All solvents and chemicals were used as purchased from commercial 
suppliers. 1H NMR spectra were obtained on a Bruker Avance III 500 MHz NMR 
spectrometer. Chemical shifts are expressed in parts per million (ppm, δ), relative to 
tetramethylsilane (TMS) as internal reference. Signals are described as s (singlet), d 
(doublet), dd (doublet of doublets), dt (doubles of triplets), t (triplet), q (quartet), or p 
(pentet).
2.3.2 2-chloro-7-ethoxy-3-(3-(4-iodophenyl)-4,5-dihydro-1H-pyrazol-5-
yl)quinoline (7a)—NaOH (0.83 mL, 2.5 M in water, 2.07 mmol) was added dropwise to a 
solution of 4-iodoacetophenone (0.36 g, 1.47 mmol) and 2-chloro-7-ethoxyquinoline-3-
carbaldehyde (0.35 g, 1.47 mmol) in EtOH (12 mL). After stirring for a 45 min at 40 °C, the 
reaction mixture was quenched with HCl (1.38 mL, 3 M). The crude mixture containing the 
resulting enone was then filtered, thoroughly washed with EtOH, and used in the next step 
without further purification. Hydrazine monohydrate (0.36 mL, 7.33 mmol) was added 
dropwise to a suspension of the enone obtained in the previous step in EtOH (30 mL). The 
mixture was refluxed for 1.5 h with stirring, after which it was allowed to cool to room 
temperature. The obtained solid was filtered and washed with EtOH. Further purification by 
trituration with EtOH furnished the title compound as an off-white solid (0.57 g, 81% over 2 
steps). 1H NMR (500 MHz, DMSO-d6) δ 1.41 (t, J=7.0 Hz, 3H), 2.89 (dd, J=16.5, 10.0 Hz, 
1H), 3.67 (dd, J=16.5, 11.0 Hz, 1H), 4.20 (q, J=7.0 Hz, 2H), 5.19 (dt, J=10.5, 3.5 Hz, 1H), 
7.27 (dd, J=9.0, 2.5 Hz, 1H), 7.34 (d, J=2.5 Hz, 1H), 7.44 (d, J=8.5 Hz, 2H), 7.74 (d, J=8.5 
Hz, 2H), 7.84 (d, J=3.5 Hz, 1H), 7.97 (d, J=9.0 Hz, 1H), 8.42 (s, 1H).
2.3.3 4-(5-(2-chloro-7-ethoxyquinolin-3-yl)-3-(4-iodophenyl)-4,5-dihydro-1H-
pyrazol-1-yl)-4-oxobutanoic acid (9a or TDRL-551)—A round-bottom flask coupled 
with a reflux condenser and containing a dry mixture of 2-chloro-7-ethoxy-3-(3-(4-
iodophenyl)-4,5-dihydro-1H-pyrazol-5-yl)quinoline (7a) (0.6 g, 1.25 mmol) and glutaric 
anhydride (0.14 g, 1.25 mmol) was immersed into a preheated oil bath (65 °C). CHCl3 (24 
mL) was then added through the condenser in one portion. The resulting solution was 
refluxed for 1.5 h with stirring, after which it was allowed to cool to room temperature. The 
obtained solid was filtered and washed with ethyl acetate. Further purification by trituration 
with ethyl acetate yielded acid 9a as an off-white solid (0.53 g, 72%). 1H NMR (500 MHz, 
DMSO-d6) δ 41.40 (t, J=7.0 Hz, 3H), 1.83 (p, J=7.5 Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 2.82 
(dt, J=15.0, 7.5 Hz, 1H), 2.91 (dt, J=15.0, 7.5 Hz, 1H), 3.28 (dd, J=18.0, 5.5 Hz, 1H), 3.97 
(dd, J=18.0, 12.0 Hz, 1H), 4.19 (q, J=7.0 Hz, 2H), 5.83 (dd, J=12.0, 5.5 Hz, 1H), 7.26 (dd, 
J=9.0, 2.5 Hz, 1H), 7.35 (d, J=2.5 Hz, 1H), 7.57 (d, J=8.5 Hz, 2H), 7.84 (d, J=8.5 Hz, 2H), 
7.93 (d, J=9.0 Hz, 1H), 7.99 (s, 1H), 12.09 (s, 1H).
2.4 Cell Culture
A2780 cells and A2780/R cells were purchased from Sigma. All other cell lines were from 
ATCC and routinely tested for mycoplasma contamination. Cells were maintained in RPMI 
media supplemented with 10% FBS (Atlanta Biological), penicillin and streptomycin. 
Cultures were incubated at 37 °C in 5% CO2 and sub-cultured 2–3 times per week.
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2.4.1 Clonogenic survival assays—Cells were plated in a 6 well (100,000 cells/well) 
or 24 well (25,000 cells/well) plate, incubated for at least 18 hours and then treated with Pt/
etoposide and/or RPA inhibitors. After 48 hours of treatment, the cells were re-plated in 10 
cm dishes (500–1000 cells/dish) and incubated for 8–10 days to allow colony formation. 
Plates were then washed with PBS, fixed with glutaraldehyde (Fisher Scientific) and stained 
with crystal violet (Acros Organics). The colonies were then counted using an Acolyte 
Synbiosis colony counter, viability determined versus vehicle controls which were plotted 
versus drug concentration.
2.4.2 Assessment of Synergy via Combination Index—In the combination index 
studies, the A2780 cells were treated with RPA inhibitor and Pt/etoposide alone as well as 
the combination of both – the inhibitor and the DNA damaging chemotherapeutic agent. The 
range of treatment was dependent on the IC50 of each inhibitor/drug. If the IC50 was X, then 
the cells were treated at a range of X/4 to 3X concentration in a colony formation assay. The 
kill curves from both the single agent treatments as well as the combination treatment were 
used in a Chou-Talalay based method to determine the combination index (CI) at different 
fractions of cells affected [30;31]. A CI > 1 indicates antagonism between the two agents, 
while a CI < 1 indicates synergy. A CI of 1 demonstrates an additive effect.
2.5 Compound-DNA binding assay
A competitive DNA intercalation assay was performed using SYBR-Green (Sigma) and 
salmon sperm DNA (Fisher). Reactions were carried out in 25 mM MOPS (pH 6.5) 
containing 30 μM sonicated salmon sperm DNA, SYBR-Green and varying concentrations 
of RPA inhibitors. Reactions were performed in a black 96-well plate in a final volume of 
110 μl. Doxorubicin, a known non-covalent DNA binding chemotherapeutic, was used as a 
positive control. Fluorescence was measured using a BioTek® Synergy™ H1 hybrid multi-
mode microplate reader with an excitation wavelength of 485 nm, emission wavelength of 
528 nm and a read height of 7 mm. Data were collected using BioTek® Gen5™ reader 
software. Reactions were incubated a maximum of 5 minutes before measurements were 
collected.
2.6 In vivo Analysis of TDRL-551
Non-obese diabetic/severe combined immunodeficient mice (NOD/SCID) were obtained 
from The Jackson Laboratory (http://www.jax.org). All animal studies were conducted 
under the guidelines of the NIH and were approved by the Institutional Animal Care and 
Use Committee of Indiana University School of Medicine. Animals were maintained under 
pathogen-free conditions and a 12-hour light-dark cycle. The safety and tolerability of 
TDRL-551 was assessed in naïve NOD/SCID mice. Mice were treated IP with increasing 
concentrations of TDRL-551 in a formulation consisting of 20% DMSO, 10% Tween 80, 
70% PBS. Based on preliminary PK analysis and a half-life of ~7 hours (data not shown) we 
administered 3 doses per week for two weeks and measured body weight every other day.
To assess anti-cancer efficacy the hind flanks of sixty 8–10 week old mice were implanted 
with 2 × 106 H460 NSCLC cells in matrigel. Tumor volumes were monitored by caliper 
measurement [tumor volumes = length × (perpendicular width)2 × 0.5]. Mice with tumors 
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ranging between 32–152.5mm3 8 days following implantation were randomized into 4 
treatment arms. Carboplatin was dissolved in water and administered via intraperitoneal 
injection at 50 mg/kg on days 8, 14, and 20 following implantation. TDRL-551 was 
suspended in 20% DMSO, 10% Tween 80, 70% PBS and administered via intraperitoneal 
injection at 200 mg/kg biweekly on days 8, 10, 14, 17, and 20. Vehicle controls were 
administered to arms not receiving indicated treatments. Tumor volumes were monitored 
biweekly as indicated and the results are presented as the average tumor volume ± standard 
error of the mean for each group (n=14 per group).
3. Results
3.1. Screening TDRL-505 analogs
Toward improving the potency and physiochemical properties of TDRL-505, we screened 
26 analogous compounds to assess their ability to inhibit RPA-DNA binding activity. These 
26 compounds shared the same 2-pyrazoline core structure as TDRL-505, but differed in 
either the type/length of the side chain attached to N1, the substitution of the phenyl group at 
C3, or the type of aromatic ring at C5. Data from a representative of 12 compounds are 
shown in Figure 1A along with quantification of the data in Figure 1B. Each of the analogs 
that displayed inhibitory activity towards RPA was titrated over a range of concentrations to 
determine IC50 values (Figure 1C). These data were used to determine SAR. We identified 
three important aspects of the molecules: the length of the carboxylic acid chain, the halogen 
on the phenyl ring, and the alkyl ether in the quinoline ring (Figure 1D). Consequently, we 
pursued an organic synthesis scheme to prepare additional TDRL-505 analogs and further 
interrogate the structure activity relationships.
3.2. Chemistry
The synthetic approach developed for the preparation of TDRL-505 analogs is depicted in 
Figure 2 and involved 5 steps. Quinolines carbaldehydes 4 were prepared by acylation of 
alkoxyanilines 2 with acetic anhydride 1, followed by Vilsmeier-Haack formylation 
[Herbert]. Aldol condensation/dehydration with a corresponding methyl ketone 5 and 
sodium hydroxide yielded enones 6, which, upon treatment with hydrazine, afforded 2-
pyrazolines 7. Lastly, acylation at N1 of the pyrazoline core with a cyclic anhydride 8 
furnished oxoacids 9. The list of all the synthesized TDRL-505 analogs is shown in Table1.
3.3. In vitro inhibition of RPA’s DNA binding activity
The in vitro inhibition of RPA’s DNA binding activity was determined by titrating all 
synthesized TDRL-505 analogs over a range of concentrations from 0–125 μM in an EMSA 
based assay (Table 1). We observed a slight increased potency by addition of a methylene 
group to the oxocarboxylic acid moiety (entries 1 and 4, and 2 and 6). Additionally, we 
found a correlation between the identity of the halogen atom on the phenyl ring and the 
effectiveness of the compound. Iodine imparted the best inhibitory activity, followed by 
bromine, chlorine (data not shown) and fluorine, in that order (entries 2 and 3, 4 and 8, and 
5 and 6). The pattern of halo-substitution on the phenyl ring was also evaluated. Since the 
meta-iodo isomer did not exhibit any effect over its para analog (entries 8 and 10), we 
pursued the latter due to its simpler purification process. Lastly, a fluorinated substituent, the 
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trifluoromethoxy group, did not alter the potency of the compound when compared to the 
parental bromo substitution (entries 4 and 9). Another part of the molecule that was subject 
of analysis was the alkyl ether moiety on the quinoline ring. The replacement of the ethyl 
group by either a methyl or isopropyl counterpart resulted in a slight decrease in inhibitory 
activity (entries 1 and 2, and 4, 6 and 7). Of all analogs tested, TDRL-551 (entry 8) 
exhibited the highest in vitro, as well as cellular, activity.
To further interrogate the most potent compound TDRL-551, we directly compared its 
activity to that of the parent compound, TDRL-505. The data presented in Figure 3A 
compare the EMSA based in vitro inhibitory activity of TDRL-551 with that of TDRL-505. 
The IC50 values, calculated form the plotted graphs (Figure 3B), were found to be 18 and 38 
μM, respectively, making TDRL-551 greater than twice as potent than its predecessor. The 
two potential mechanisms for inhibition are either a direct interaction with the protein or an 
interaction with the DNA that renders it unable to bind to the protein. Our previous in silico 
docking analyses suggested that the 505 class of compounds inhibits DNA binding activity 
via a direct interaction with the protein RPA [27]. To confirm the mechanism of inhibition 
for 551 was via an interaction with RPA and not DNA we assessed the ability of TDRL-551 
to bind to DNA using a fluorescence displacement assay. The results presented in Figure 3C 
demonstrate that no DNA binding activity was observed for 551 and confirm that the 
compound inhibits the protein-DNA interaction by binding directly to the RPA protein and 
not via binding to the DNA. To further delve into the mechanism of binding, we tested 
whether TDRL-551 could inhibit RPA DBD-A/B binding (the major high affinity DNA 
binding core) to DNA. Both TDRL-551 and TDRL-505 inhibit RPA DBD-A/B-DNA 
interaction and hence employ a similar inhibition mechanism (Figure 3D).
3.4. Cellular activity of TDRL-551
3.4.1. Single agent anti-cancer activity of RPA inhibitors in EOC cell line—
Considering the essential role of RPA in S-phase DNA replication [32] and our previous 
data with both reversible and irreversible RPA inhibitors [25;27], we evaluated the 
TDRL-505 analogs for single agent anti-cancer activity in the A2780 EOC cell line using 
clonogenic survival assays (Table 1). Consistent with our in vitro EMSA based studies, 
TDRL-551 showed the best single agent activity in these cells. Also in line with the in vitro 
results was the relative cellular inhibitory activity of all tested compounds. Figure 4A shows 
the data obtained from clonogenic survival assays, comparing the single agent activity of our 
original lead TDRL-505 and our optimized lead, TDRL-551. TDRL-505’s IC50 was found 
to be 55 μM, while TDRL-551 was twice as potent with an IC50 of 25μM. Interestingly, the 
degree of improvement in potency remained consistent between the in vitro and cellular 
assays. To ensure that the activity was not cell line specific, we also assessed the single 
agent activity of TDRL-551 in three other EOC cell lines, SKOV3 and OVCA429 (ATCC) 
both of which were isolated from patients with recurrent ovarian cancer following platinum 
therapy and the cisplatin resistant A2780 derivative [33]. We also assessed activity in the 
H460 NSCLC cell line. In each case, TDRL-551 displayed single agent activity similar to 
that observed in the parental A2780 EOC cells (Figure 4B) demonstrating that, as would be 
expected for an RPA inhibitor, the mode of activity is not restricted to a single cell line or 
cancer type.
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3.4.2. Synergy with DNA damaging chemotherapeutic agents in EOC—Since 
repair and tolerance of Pt-DNA lesions predominantly occur via NER and HR, cellular 
inhibition of RPA should have a dramatic effect on the sensitization of cancer cells to Pt. In 
order to determine whether inhibition of RPA with TDRL-551 synergizes with Pt in EOC 
cells, we performed combination treatment studies with TDRL-551 and cisplatin. We used 
the platinum sensitive A2780 cell line as our cell culture model for EOC. Figure 4C shows 
an average of three biological replicate experiments for combination studies of TDRL-551 
with Pt in A2780 cell line with appropriate single agent controls. Our data show a 
synergistic effect indicated by a CI < 1 at 0.5 or higher fraction of cells affected. The data 
obtained are consistent with our hypothesis that RPA inhibition makes cancer cells more 
sensitive towards Pt and hence acts synergistically with cisplatin treatment. Since RPA also 
plays a crucial role in replication, we also tested TDRL-551 in combination with etoposide, 
a topoisomerase II inhibitor. TDRL-551 was mildly synergistic with etoposide at the highest 
fraction of cells affected (> 0.8) (Figure 4C).
3.5. RPA Inhibitor TDRL-551 displays single agent anti-cancer activity and sensitizes 
NSCLC tumors to platinum based treatment in vivo.
To determine the effect of RPA inhibition via TDRL-551 treatment in vivo we first assessed 
tolerability and experiments demonstrated a good safety profile with no weight loss 
observed with intraperitoneal administration up to 200 mg/kg (Figure 5A). A slight decrease 
in body weight was observed at 300 mg/kg, but still did not reach greater than 10% loss of 
weight. Co-treatment with carboplatin was also assessed and again, no adverse effects or 
loss of weight was observed up to 200 mg/kg (data not shown). We then determined anti-
cancer activity in H460 NSCLC xenografts. Initial pharmacokinetic analysis revealed that 
ability to achieve a plasma concentration of >20 μM with a half-life of over 7 hours (data not 
shown). Tumor cells were therefore implanted in NOD/SCID mice that were randomized 
and treated with vehicle, TDRL-551; carboplatin; or the combination of TDRL-551 and 
carboplatin (Figure 5B). Carboplatin is often used in the treatment of NSCLC and forms 
DNA adducts chemically indistinguishable from those forms with cisplatin. As a result of 
the similarity in the DNA adducts formed between carboplatin and cisplatin, the repair 
pathways that impact sensitivity are identical. Tumor volumes were monitored for 2 weeks 
following initiation of treatment regimens and averages for each treatment arm are reported. 
Each of the treatment arms is clearly distinct from the untreated control group. Carboplatin 
treatment and TDRL-551 displayed similar growth inhibition of tumors. This demonstrates 
single agent anti-cancer activity of TDRL-551 in vivo that is consistent with the cellular 
assays reported above. Interestingly, mice receiving carboplatin and TDRL-551 
demonstrated the slowest tumor growth, consistent with TDRL-551 sensitizing cells to 
platinum. These data provide strong evidence that TDRL-551 can be used to sensitize 
NSCLC tumors to Pt-based therapy.
4. Discussion
The research presented in this article describes the synthesis, structure activity relationships 
and in vitro and cellular activity of novel reversible RPA inhibitors in EOC and NSCLC. We 
have demonstrated both single agent activity and synergy in combination with DNA 
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damaging chemotherapeutic agents; cisplatin and etoposide. In vivo data demonstrate no 
overt toxicity and good clinical efficacy in combination with carboplatin in a NSCLC 
xenograft model. This represents the first in vivo deployment of a small molecule inhibitor 
targeting the RPA-DNA interaction. The SARs defined the necessary substituents for 
activity while maintaining excellent bioavailability. These data demonstrate that to achieve 
in vivo activity a balance between potency and bioavailability can lean towards lower 
affinity as long as PK parameters allow clinically effective concentrations to be maintained. 
This balance is especially important in targeting RPA an essential protein with homozygous 
mutations being embryonically lethal in mice, while heterozygous mutants having an early 
predisposition to cancer [34]. No loss of function mutation for RPA has been reported in 
humans and genetic knockdown of RPA affects cellular viability [32]. Consequently, 
targeting RPA could have potential negative effects on rapidly dividing healthy cells, such 
as gut epithelial, hematopoietic, or hair follicle, and it could lead to unwanted side effects. 
For this reason, exploiting the separation of function phenomena in RPA in a manner 
amenable for therapeutic intervention is crucial. Our laboratory has previously published 
minimal cytotoxic effects on peripheral blood lymphocytes with the TDRL-505 inhibitor 
[27]. Moreover, our preliminary mouse toxicity studies indicate no significant overall 
change in body weight for doses up to 200 mg/kg, but show anti-tumor activity at the same 
dosage in a lung cancer xenograft model. We hypothesize that since cancer cells are 
undergoing an abnormal unregulated rate of proliferation, they are in a state of replicative 
stress and their dependence on RPA can be used to obtain a therapeutic window without 
harming the normal cells. This can also be understood by analogy to an oncogene addiction 
model, in which cancer cells have a higher dependence on the oncogene compared to normal 
cells and hence can be selectively targeted. Finally, RPA’s overexpression has been 
correlated with multiple cancers like breast, lung and colon, and it has also been associated 
with metastasis [35–38]. Thus, clinical reports of altered RPA expression in a variety of 
cancers make RPA a promising novel therapeutic target.
It is also important to elucidate whether our inhibitors exclusively impair the repair function 
of RPA without compromising its role in replication. Our previously published data with 
inhibitor TDRL-505 demonstrate a G1 cell cycle arrest, however the cells that are already in 
S-phase progress through the replication phase [27]. This indicates that our inhibitors are 
either blocking the initial phase of replication initiation or early origin firing and inhibiting 
the transition from G1 to S phase, or causing an alteration in the DNA damage checkpoint 
signaling. In either case, the 505 class of inhibitors do not block progression through S-
phase once the G1-S transition has occurred. We also have demonstrated that 505 and 551 
have a similar mechanism and target the DBD-A/B domain of RPA. Interestingly, we did 
not observe a significant difference in the inhibition potency of TDRL-505 and TDRL-551 
for RPA DBD-A/B. We speculate the improved potency of TDRL-551 for full length RPA 
could be due to its binding at other sites in RPA and thus the overall potency of the molecule 
could be a result of multiple binding sites.
Our current results demonstrating synergy of TDRL-551 with Pt in an EOC cell line, along 
with our published data showing synergy of TDRL-505 with Pt in a lung cancer cell line 
indicates that our RPA inhibitors are impairing the repair function of RPA. The major 
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limitation for successful treatment of a variety of cancers, including EOC, has been the 
tolerance and repair of Pt-DNA adducts and has been specifically correlated to increased 
repair in a variety of ovarian cancer cell lines [12]. Hence, inhibiting DNA repair by 
targeting RPA could have a major significance for cancer therapy.
We also examined the ability of TDRL-551 to synergize with etoposide, a topoisomerase II 
inhibitor. Etoposide treatment leads to both single and double stranded DNA breaks as well 
as stalling and collapse of replication forks [39;40]. Inhibiting RPA’s replication function 
could further enhance the number of DNA breaks produced on etoposide treatment and 
improve the effectiveness of the treatment. Although TDRL-505 has been previously shown 
to be highly synergistic with etoposide in lung cancer cells through a flow cytometry based 
Annexin-PI staining assay [27], its optimized analog, TDRL-551, showed modest synergy 
with etoposide at the highest fractions of cells affected (> 0.8) in A2780 EOC cell line 
through colony formation assay. Compound TDRL-551 may be more specific in targeting 
the repair function of RPA than its predecessor TDRL-505 and hence doesn’t significantly 
impact replication and only mildly synergizes with etoposide. Alternatively, the differences 
may be a function of the cell lines used and cancer types being investigated. While cisplatin 
and etoposide are the standard drugs used in treatment against lung cancer, the therapy for 
ovarian cancer involves the combination of platinum and taxol. Etoposide is not a first line 
therapy for EOC and hence improving its effectiveness may be limited based on the cancer. 
Lastly, we cannot rule out that the differing synergy outcomes are a consequence of the type 
of assay performed in each case. Despite these caveats, the important finding is that RPA 
inhibition with TDRL-551 synergizes with cisplatin in EOC and may provide an avenue to 
increase sensitivity to platinum in the clinic.
RPA inhibitors can be used as DNA repair inhibitors to overcome resistance to platinum 
based chemotherapies. Inhibiting DNA repair with SMIs can be used in combination with Pt 
both at first line and second line stage of therapy. In first line therapy, Pt in combination 
with RPA inhibitors could lead to maximum effectiveness by killing the majority of cancer 
cells, which are now sensitized to Pt due to inhibition of DNA repair. This may certainly 
still lead to some surviving cancer cells that are resistant to the treatment due to other 
mechanisms, such as reduced uptake of platinum, increased drug efflux, or increased 
expression of proteins like glutathione that bind and inactivate Pt in the cells. However, 
since there will be less number of surviving cancer cells to relapse with platinum resistant 
forms, any increase in the effectiveness of the first line therapy would lead to an improved 
progression free survival (PFS), which can be clinically significant. As second line therapy, 
RPA inhibitors can be used in combination with Pt to re-sensitize the platinum resistant 
cancers, also leading to an increase in PFS. It is important to mention that platinum based 
chemotherapy is not the only scope for the utility of RPA inhibitors. Since RPA plays a 
variety of roles in different pathways, its other functions can also be targeted. For instance, 
RPA inhibitors can be used in combination with radiation therapy that induces double 
stranded breaks (DSB). Thus, inhibiting RPAs role in HR-dependent DSB repair would be 
expected to enhance the effectiveness of radiotherapy. In conclusion, RPA inhibitors can be 
used in a multitude of platforms with a special focus in the area of cancer therapy.
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Figure 1. EMSA screening of TDRL-505 analogs
A) 12 TDRL-505 analogs were screened using the EMSA assay for RPA-DNA inhibition 
activity at 100 μM. The free DNA and RPA-DNA complexes are indicated. The asterisk 
indicated the position of the E. coli SSB-DNA complex. B) Quantification of duplicate 
determinations were averaged and plotted as a percent of control with bars representing the 
range of values C) Structures of compounds with their corresponding IC50 values (μM) 
calculated from EMSA reactions as described in Methods. Compounds were titrated at a 
range of 1–125 μM. D) SAR identified areas of interest and they are highlighted by the 
colored ovals.
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Figure 2. Synthesis of TDRL-505 analogs
Reagents and conditions: (a) DIEA, DMAP, DCM, rt, 2 h, 90–100%. (b) (i) DMF, POCl3, 0 
°C, 20 min, (ii) Amide, 110 °C, 2.5 h, 44–64%. (c) NaOH 10%, EtOH, 45 °C, 45 min. (d) 
H2N-NH2.H2O, EtOH, reflux, 1.5 h, 73–81% (over 2 steps). (e) CHCl3, reflux 1.5 h, 40–
72%.
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Figure 3. In vitro analysis of TDRL-551 inhibitory activity
A) RPA was incubated with compounds TDRL-505 and TDRL-551 ranging from 1–125 
μM. DNA binding was analyzed by EMSA as described in Methods. The position of free 
DNA and the DNA–RPA complex is denoted in the figure. The asterisk indicates the 
position of the E. coli SSB-DNA complex. B) Quantification of the data presented in panel 
A. Data represent the average and SD of three independent determinations and the data were 
fitted using nonlinear regression analysis (Sigmaplot) to obtain IC50 values. C) Fluorescent 
displacement assays were performed as described and the indicated concentration of 551 or 
doxorubicin was titrated into reactions containing DNA and SybrGreen. The fluorescence 
was measured and data represent the average and SD of three independent determinations. 
D) RPA-A/B Box was incubated with compounds TDRL-505 and TDRL-551 ranging from 
25–100 μM. DNA binding was analyzed by EMSA as described in Methods. The position of 
free DNA and the DNA–RPA A/B complex is denoted in the figure.
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Figure 4. Cellular activity of TDRL-551
A) A2780 cells were treated with RPA inhibitor TDRL-505 or TDRL-551 for 48 hours and 
viability was assessed in a colony formation assay as described in Methods. The colonies 
were counted and normalized to the untreated controls to determine cellular viability. The 
data represent the average and SEM from three independent determinations and the data 
were fit using non- linear regression analysis (Sigmaplot) to calculate cellular IC50s. B) 
Analysis of TDRL551 single agent activity in H460 NSCLC, SKOV3, A2780/R and 
OVCA429 EOC cells as described in panel A. C) The CI of TDRL-551 with Pt and 
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Etoposide were determined through a Chou-Talalay based approach as described in the 
Methods. The data represent the average and SEM from three independent determinations
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Figure 5. In vivo analysis of TDRL-551
A) Acute toxicity and tolerability of TDRL-551 was assessed via body weight 
determinations following triweekly dosing at the indicated drug concentrations. Mice were 
treated on days 1, 3, 5, 8, 10, and 12 IP as described in Methods. Data are reported as the 
percent of body weight on day 1 and represent the mean ± standard error of the mean (n=3). 
B) In vivo anti-cancer activity was assessed in human H460 NSCLC tumor xenografts in 
NOD/SCID mice. Mice were implanted on day 1, tumor measured by calipers and individual 
mice randomly assigned to one of 4 treatment arms. Carboplatin was administered once per 
week on days 8, 14 and 20. TDRL 551 was administered biweekly on days 8, 10, 14, 17, and 
20. Tumor volumes were monitored by caliper measurement [tumor volume = length 
(perpendicular width)2 × 0.5] biweekly as indicated. Average tumor volume ± standard error 
of the mean for each group is reported in mm3 (n=14).
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